DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, will present new findings that showcase the benefits of its glucose biosensing technology for people with all types of diabetes and ...

Dexcom's Apple Watch app will be ready to go when the device launches in April, the company told the Wall Street Journal. The app, which will not need to seek pre-market approval from the FDA thanks ...

DexCom (NasdaqGS:DXCM) is seeing higher adoption of its continuous glucose monitoring systems among patients using GLP-1 drugs, as physicians pair both therapies for diabetes care. The company is ...

Dexcom will stop producing G6 CGM sensors July 1, 2026, urging patients to switch to the smaller, more accurate G7 model.

A survey conducted by the continuous glucose monitor maker Dexcom found that just over half of healthcare providers ranked technology and education as having larger impacts when it comes to treating ...

But what if companies outside of the pharmaceutical industry benefit as well? One excellent candidate to do so is DexCom ...

The FDA has approved San Diego, California-based Dexcom for a Bluetooth-enabled continuous glucose monitor (CGM), called the G5 Mobile CGM system. Correction: A previous version of this article ...

Add Yahoo as a preferred source to see more of our stories on Google. Dexcom recalled an Android app for its G6 continuous glucose monitor because of a problem with the app stopping unexpectedly.

Add Yahoo as a preferred source to see more of our stories on Google. Your device's unique device identifier and model number are on the back of your receiver. Some of Dexcom's continuous glucose ...

New RAMQ coverage means eligible Québec residents with type 2 diabetes on intensive insulin therapy can now access Dexcom Continuous Glucose Monitoring (CGM) to simplify diabetes management. Dexcom, ...